DK1559715T3 - N-{2-chlor-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) - ureasalt i krystallinsk form - Google Patents

N-{2-chlor-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) - ureasalt i krystallinsk form

Info

Publication number
DK1559715T3
DK1559715T3 DK03756734T DK03756734T DK1559715T3 DK 1559715 T3 DK1559715 T3 DK 1559715T3 DK 03756734 T DK03756734 T DK 03756734T DK 03756734 T DK03756734 T DK 03756734T DK 1559715 T3 DK1559715 T3 DK 1559715T3
Authority
DK
Denmark
Prior art keywords
quinolyl
isoxazolyl
dimethoxy
chloro
oxy
Prior art date
Application number
DK03756734T
Other languages
English (en)
Inventor
Naoki Matsunaga
Satoshi Yoshida
Ayako Yoshino
Tatsuo Nakajima
Original Assignee
Kirin Brewery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Brewery filed Critical Kirin Brewery
Application granted granted Critical
Publication of DK1559715T3 publication Critical patent/DK1559715T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK03756734T 2002-10-21 2003-10-21 N-{2-chlor-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) - ureasalt i krystallinsk form DK1559715T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002306101 2002-10-21
PCT/JP2003/013439 WO2004035572A1 (ja) 2002-10-21 2003-10-21 Ｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キノリル）オキシ］フェニル｝−ｎ’−（５−メチル−３−イソキサゾリル）ウレアの塩の結晶形

Publications (1)

Publication Number Publication Date
DK1559715T3 true DK1559715T3 (da) 2007-12-27

Family

ID=32105192

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03756734T DK1559715T3 (da) 2002-10-21 2003-10-21 N-{2-chlor-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) - ureasalt i krystallinsk form

Country Status (10)

Country Link
US (1) US7166722B2 (da)
EP (1) EP1559715B1 (da)
JP (1) JP3763414B2 (da)
AT (1) ATE374199T1 (da)
AU (1) AU2003301430A1 (da)
DE (1) DE60316590T2 (da)
DK (1) DK1559715T3 (da)
ES (1) ES2294317T3 (da)
PT (1) PT1559715E (da)
WO (1) WO2004035572A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513006A (en) * 1999-01-22 2003-10-31 Kirin Brewery Quinoline derivatives and quinazoline derivatives
EP2277867B1 (en) 2002-07-15 2012-12-05 Symphony Evolution, Inc. Compounds, pharmaceutical compositions thereof and their use in treating cancer
DK2392564T3 (da) 2003-09-26 2014-01-13 Exelixis Inc c-Met-modulatorer og anvendelsesfremgangsmåder
JP2008514657A (ja) * 2004-09-29 2008-05-08 バイエル・ヘルスケア・アクチェンゲゼルシャフト ４−｛４−［（｛［４−クロロ−３−（トリフルオロメチル）フェニル］アミノ｝カルボニル）アミノ］フェノキシ｝−ｎ−メチルピリジン−２−カルボキサミドの製造方法
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US9037466B2 (en) * 2006-03-09 2015-05-19 Nuance Communications, Inc. Email administration for rendering email on a digital audio player
SG173014A1 (en) 2009-01-16 2011-08-29 Exelixis Inc Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US7998973B2 (en) * 2009-11-13 2011-08-16 Aveo Pharmaceuticals, Inc. Tivozanib and temsirolimus in combination
WO2012044572A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases
BR112013020362A2 (pt) 2011-02-10 2018-05-29 Exelixis Inc processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
CN102532116B (zh) * 2011-08-09 2015-01-21 武汉迈德森医药科技有限公司 抗肿瘤靶向治疗药物tivozanib的合成方法
CN104072492A (zh) * 2013-11-27 2014-10-01 苏州摩尔医药有限公司 一种抗肿瘤靶向治疗药物Tivozanib的合成方法
EP3513809B9 (en) 2016-09-13 2022-07-13 Kyowa Kirin Co., Ltd. Medicinal composition comprising tivozanib
AU2019375972A1 (en) 2018-11-05 2021-05-27 Aveo Pharmaceuticals, Inc. Use of tivozanib to treat subjects with refractory cancer
WO2023096651A1 (en) 2021-11-26 2023-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treating bile duct cancers with tivozanib
CN114213404A (zh) * 2021-12-27 2022-03-22 武汉九州钰民医药科技有限公司 Vegfr抑制剂替沃扎尼的合成工艺

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ299156B6 (cs) * 1997-12-22 2008-05-07 Bayer Corporation Substituované heterocyklické mocoviny, farmaceutické prípravky je obsahující a jejich použití
EP1243582A4 (en) * 1999-12-24 2003-06-04 Kirin Brewery CHINOLINE AND CHINAZOLINE DERIVATIVES AND MEDICATIONS CONTAINING THEM
EP1415987B1 (en) * 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
DK1382604T3 (da) * 2001-04-27 2006-04-18 Kirin Brewery Quinolinderivater med en azolylgruppe og quinazolinderivater
AU2003292838A1 (en) * 2002-12-27 2004-07-29 Kirin Beer Kabushiki Kaisha Therapeutic agent for wet age-related macular degeneration

Also Published As

Publication number Publication date
ES2294317T3 (es) 2008-04-01
PT1559715E (pt) 2007-10-24
EP1559715A4 (en) 2006-03-29
US20060052415A1 (en) 2006-03-09
EP1559715B1 (en) 2007-09-26
JP3763414B2 (ja) 2006-04-05
DE60316590D1 (en) 2007-11-08
ATE374199T1 (de) 2007-10-15
US7166722B2 (en) 2007-01-23
DE60316590T2 (de) 2008-06-19
EP1559715A1 (en) 2005-08-03
AU2003301430A1 (en) 2004-05-04
JPWO2004035572A1 (ja) 2006-02-16
WO2004035572A1 (ja) 2004-04-29

Similar Documents

Publication Publication Date Title
DK1559715T3 (da) N-{2-chlor-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) - ureasalt i krystallinsk form
RU2207341C2 (ru) Новые циклические соединения диамина, содержащие их лекарственные средства и способы лечения
RU2325389C2 (ru) Композиция и производные замещенного азаиндолоксоацетапиперазина, обладающие противовирусной активностью
WO2004026863A8 (en) Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
IS2718B (is) Taxól-eflandi efnasambönd
NZ528851A (en) N-aroyl cyclic amines
SE0102300D0 (sv) Compounds
RU99128053A (ru) Новые циклические соединения диамина и содержащие их лекарственные средства
BR9812046A (pt) Compostos, processos para a preperação do composto e para tratar um paciente humano ou animal, composição farmacêutica, e, uso de um composto
NO912410L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocyklen-derivater.
HU9600834D0 (en) Quinazoline derivatives
BR0015193A (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma condição associada com trasmissão reduzida de nicotina, para tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para tratamento ou profilaxia de doenças ou condições humanas
BRPI0412219B8 (pt) compostos ômega-carboxi aril difenil uréia fluoro substituídos e composições farmacêuticas compreendendo os referidos compostos
NO20050573L (no) 4-'7-halo-2-quino (XA) linyloksy ! fenoksypropionsyrederivater som antineoplastiske midler
BR9304910A (pt) Composto, processo para a sua preparação, medicamento, processo para a sua preparação e aplicação do dito composto
IT1226727B (it) Farmaci precursori della dopamina.
RU2003103780A (ru) Соединения фенилпиридазина и содержащие их лекарственные средства
NO20040881L (no) Orale antidiabetes midler.
DK1465625T3 (da) Opløste topoisomerase-gifte
RU2008127260A (ru) Производные хиназолинона в качестве антагонистов ваниллоидов
DK0397365T3 (da) Arylthiazolylimidazoler som 5HT3-antagonister
ATE361918T1 (de) 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2- yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden
ATE137501T1 (de) Benzazin-verbindungen und deren pharmazeutische verwendungen
ES2089974B1 (es) Utilizacion de los derivados de 1-(4-)4-aril (o heteroaril)-1-piperazinil)-butil)-1-h-azol para la preparacion de medicamentos destinados al tratamiento de los trastornos de la secrecion gastrica.
ATE141605T1 (de) Thienotriazoldiazepinverbindungen und deren pharmazeutische anwendungen